Success Story: NIW Approved for a Bangladeshi Postdoctoral Research Associate Advancing Cancer Therapeutics
Client’s Testimonial:
“I had a very positive experience working with Chen Law Group on my I-140 petition. From start to approval, the team was professional, responsive, and detail oriented. They clearly explained each step of the process, addressed my questions and handled my case with great care and expertise. My I-140 was approved smoothly, and I am very satisfied with the service I received. I would confidently recommend Chen Law Group to anyone seeking reliable and knowledgeable immigration legal support.”
On January 16th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Research Associate in the Field of Pharmaceutical Sciences (Approval Notice).
General Field: Pharmaceutical Sciences
Position at the Time of Case Filing: Postdoctoral Research Associate
Country of Origin: Bangladesh
State of Residence at the Time of Filing: Illinois
Approval Notice Date: January 16th, 2026
Processing Time: 17 months, 25 days (Premium Processing Requested)
Case Summary:
On January 16th, 2026, North America Immigration Law Group (Chen Immigration Law Associates) secured an EB-2 National Interest Waiver (NIW) approval for a postdoctoral research associate in pharmaceutical sciences from Bangladesh. From the outset, our team took a case-by-case approach and guided the matter through the full I-140 process, organizing the evidence under the Matter of Dhanasar framework and presenting a clear, credible record of national importance and sustained impact.
Client’s Background and Field
The client holds a Ph.D. in Clinical Pharmaceutical Sciences and works at a U.S. research institution. At the time of filing, the client was conducting research focused on understanding how cancer develops at the molecular level, including investigating mechanisms such as genome instability and replication stress. The long-term goal of this work is to identify actionable molecular targets that can support more effective and cost-conscious therapeutic strategies.
Demonstrating Impact and National Importance
In the petition, we emphasized how this research direction supports better cancer treatment outcomes and aligns with broad U.S. public health priorities. We also demonstrated that the client was well positioned to advance the proposed endeavor by documenting a strong record of peer-reviewed scholarship, independent reliance by other researchers, and peer-review invitations that reflect professional trust.
The client’s track record included 10 peer-reviewed journal articles and a first-authored abstract, with 212 citations and at least 2 completed journal peer reviews. We also highlighted objective indicators of influence, including highly cited work and strong citation percentile context within the relevant field.
Expert Endorsements
Independent recommendation letters helped translate technical contributions into real-world significance. One recommender concluded:
“In conclusion, [Client]'s leadership in pharmaceutical sciences is clearly demonstrated by his extensive publication history, spanning topics from drug discovery to infertility research. There is thus no doubt that [Client] shall continue to produce additional valuable research, both driving progress in the field and bringing immense benefits to national and international concerns.”
The ResultFiled on July 22, 2024, and approved on January 16, 2026, this NIW case was approved after 543 days, confirming that the client’s proposed endeavor has substantial merit and national importance, and that waiving the job offer requirement benefits the United States. We wish him continued success as he advances his research and builds an enduring career in the United States.